Expanded Access for Relatlimab

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

NCT05513001 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease

NCT06413511 ·Status: WITHDRAWN ·Phase: PHASE1

Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19

NCT04603651 ·Status: NO_LONGER_AVAILABLE

Safety and Efficacy of Abatacept in IgG4-Related Disease

NCT03669861 ·Status: COMPLETED ·Phase: PHASE2

Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

NCT06865651 ·Status: RECRUITING ·Phase: PHASE2

Compassionate Use of Dupilumab

NCT04776694 ·Status: APPROVED_FOR_MARKETING

Personalized Therapies in Inflammatory Complex Disease

NCT03651518 ·Status: COMPLETED ·Phase: PHASE2

A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)

NCT01066598 ·Status: TERMINATED ·Phase: PHASE2

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT06388564 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

NCT06821542 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Rituximab for Anti-cytokine Autoantibody-Associated Diseases

NCT01842386 ·Status: COMPLETED ·Phase: PHASE1

Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

NCT07011810 ·Status: RECRUITING ·Phase: PHASE2

Restoration of Endothelial Integrity in Patients With COVID-19 (RELIC)

NCT04723589 ·Status: WITHDRAWN ·Phase: PHASE2

Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness

NCT04337359 ·Status: NO_LONGER_AVAILABLE

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

NCT06163326 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

NCT06663722 ·Status: RECRUITING ·Phase: PHASE2

Long-term Extension Study of Ligelizumab in Food Allergy

NCT05678959 ·Status: TERMINATED ·Phase: PHASE3

An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies

NCT00072592 ·Status: COMPLETED ·Phase: PHASE1

An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

NCT04620811 ·Status: COMPLETED ·Phase: PHASE3

Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

NCT06046248 ·Status: RECRUITING ·Phase: PHASE2

Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis

NCT00635089 ·Status: COMPLETED ·Phase: PHASE3

Belimumab With Rituximab for Primary Membranous Nephropathy

NCT03949855 ·Status: RECRUITING ·Phase: PHASE2

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

NCT07049575 ·Status: RECRUITING ·Phase: PHASE1

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

NCT07219615 ·Status: RECRUITING ·Phase: PHASE2

Global Managed Access Program Cohort for Ligelizumab in CSU

NCT04903613 ·Status: NO_LONGER_AVAILABLE